Form 4 for ARQT Arcutis Biotherapeutics, Inc.
Accepted 2025-08-05 00:00:00 ET · period of report 2025-08-01 · accession 0001787306-25-000115 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| DM | 2025-08-05 | 2025-08-01 | ARQT | Welgus Howard G. | Dir | S - Sale+OE | $14.30 | -10.0K | 100.2K | -9% | -$143.0K |
| DM | 2025-08-05 | 2025-08-01 | ARQT | Welgus Howard G. | Dir | M - OptEx | $0.00 | +10.0K | 104.1K | +11% | $0 |
| DM | 2025-08-05 | 2025-08-01 | ARQT | Welgus Howard G. | Dir | M - OptEx | $0.00 | -10.0K | 0 | -100% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2025-08-01 | S | D | 6,110 | $14.30 | 100,206 | D | — | — | (F2) The price reported in Column 4 is a weighted average sale price. The shares were sold in multiple transactions at prices ranging from $14.14 to $14.55, inclusive. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. |
| 2 | Common | Common Stock | 2025-08-01 | M | A | 6,110 | $0.00 | 106,316 | D | — | — | (F1) The transactions reported in this Form 4 were effected pursuant to a 10b5-1 trading plan adopted on March 11, 2025, by the Reporting Person, with a plan end date of May 29, 2026. |
| 3 | Common | Common Stock | 2025-08-01 | S | D | 3,890 | $14.30 | 100,206 | D | — | — | (F2) The price reported in Column 4 is a weighted average sale price. The shares were sold in multiple transactions at prices ranging from $14.14 to $14.55, inclusive. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. |
| 4 | Common | Common Stock | 2025-08-01 | M | A | 3,890 | $0.00 | 104,096 | D | — | — | (F1) The transactions reported in this Form 4 were effected pursuant to a 10b5-1 trading plan adopted on March 11, 2025, by the Reporting Person, with a plan end date of May 29, 2026. |
| 5 | Derivative | Stock Option (right to buy) | 2025-08-01 | M | D | 6,110 | $0.00 | 0 | D | $0.58 · — to 2028-06-13 | 6,110 Common Stock | (F3) This option is fully vested. |
| 6 | Derivative | Stock Option (right to buy) | 2025-08-01 | M | D | 3,890 | $0.00 | 0 | D | $1.68 · — to 2029-03-13 | 3,890 Common Stock | (F3) This option is fully vested. |